Genitourinary Cancers | Specialty

The genitourinary cancers condition center is a comprehensive resource for clinical news and expert insights on genitourinary cancers. Read more at OncLive.

Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

September 22nd 2025

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCC

September 18th 2025

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Dr Chehrazi-Raffle on the TiNivo-2 Study of Tivozanib With/Without Nivolumab in mRCC

September 16th 2025

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Dr Chahoud on the Safety of ALLO-316 in Advanced ccRCC

September 16th 2025

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Dr Chahoud on ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma

September 9th 2025

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Zanzalintinib Plus Nivolumab Generates Early Antitumor Activity in Untreated Advanced ccRCC

September 3rd 2025

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC

September 2nd 2025

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

August 29th 2025

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Dr Vento on the Clinical Significance of Somatic NGS in Guiding Treatment Decisions for Non–Clear Cell RCC

August 27th 2025

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Dr Chahoud on the Rationale for Evaluating Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

August 20th 2025

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

Dr Vento on the Importance of Refining the Classification of RCC to Better Account for Molecular Heterogeneity

August 18th 2025

Joseph Vento, MD, discusses the importance of refining RCC classification standards to improve the field’s understanding of the disease’s heterogeneity.

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC

August 15th 2025

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Tailored Therapies Needed to Overcome Immune-Cold Microenvironment of Chromophobe RCC

August 15th 2025

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC

August 14th 2025

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Dr Pal on Future Research Directions With Adjuvant Immunotherapy in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Dr Pal on the Predictive Utility of KIM-1 Expression in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity

August 8th 2025

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.